Viking Therapeutics Inc (VKTX) Is Not Likely To Be The Same Tomorrow

After Hours

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Recently, Yahoo Finance discussed the stock, revealing that Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2023 on February 7, 2024.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Stocks Info

Viking Therapeutics Inc is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of Viking Therapeutics Inc is $2.47B. A total of 3.25 million shares were traded on the day, compared to an average of 2.65M shares.

Insider Activity

Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, VKTX has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 37 BUYs and 24 SELLs from insiders. Insiders purchased 1,349,835 shares during that period but sold 1,490,123.

In the most recent transaction, Lian Brian sold 85,000 shares of VKTX for 24.71 per share on Jan 31. After the transaction, the President & CEO now owns 2,264,882 company shares. In a previous transaction on Jan 30, Lian Brian sold 35,000 shares at 23.95 per share. VKTX shares that President & CEO owns now total 2,264,882.

Among the insiders who sold shares, Rouan Sarah Kathryn disposed of 30,000 shares on Jan 19 at a per-share price of $23.05. This resulted in the Director holding 0 shares of VKTX after the transaction. In another insider transaction, ZANTE GREG sold 15,000 shares at $17.90 per share on Jan 04. Company shares held by the Chief Financial Officer now total 180,730.

Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for VKTX in the last 3 months, the mean price target is $34.00 with high estimates of $40.00 and low estimates of $28.00. In terms of 52-week highs and lows, VKTX has a high of $25.72 and a low of $8.28.

As of this writing, VKTX has an earnings estimate of $Viking Therapeutics, Inc. per share for the current quarter. EPS was calculated based on a consensus of Vertex Pharmaceuticals Incorpor estimates, with a high estimate of $Nkarta, Inc. per share and a lower estimate of $MarketAxess Holdings, Inc.

Balance Sheet Annually/Quarterly

As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. VKTX’s latest balance sheet shows that the firm has $202.10M in Cash & Short Term Investments as of fiscal 2021. There were $29.00k in debt and $8.78M in liabilities at the time. Its Book Value Per Share was $3.68, while its Total Shareholder’s Equity was $201.88M.

Analysts Opinion

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for VKTX is Buy with a score of 4.89.

Most Popular

Related Posts